Prior* | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Cancer type | Sex | Race | Arthritis Type | Age at cancer | DMARD | Biologic | Vital status† | Country‡ | Arthritis§ duration | Cancer date |
Hodgkin's lymphoma | M | White | Enthesitis-related | 18 | No | No | Alive | CA | 2 | 2005 |
B-cell lymphocytic leukaemia | F | First Nation | Polyarticular rheumatoid factor negative | 9 | Yes | No | Deceased | USA | 4 | 2002 |
Hepatosplenic T-cell NHL | F | White | Systemic | 16 | Yes | Yes | Deceased | CA | 8 | 2009 |
Polymorphic post-transplantation lymphoproliferative disease | M | White | Polyarticular rheumatoid factor positive | 16 | Yes | Yes | Deceased | USA | 3 | 2010 |
Papillary follicular adenocarcinoma thyroid | F | White | Oligoarticular persistent | 13 | No | No | Alive | USA | 8 | 2011 |
Renal cell adenocarcinoma | F | White | Polyarticular rheumatoid factor negative | 24 | Yes | Yes | Alive | CA | 19 | 2008 |
Glioma | M | White | Oligoarticular persistent | 10 | No | No | Alive | CA | 5 | 2008 |
Primitive neuroectodermal (Ewing) cancer | F | White | Oligoarticular extended | 17 | Yes | Yes | Deceased | CA | 6 | 2009 |
Endometrial adenocarcinoma | F | White | Enthesitis-related | 30 | Yes | Yes | Alive | CA | 14 | 2011 |
*Prior DMARD=use of disease-modifying antirheumatic agent prior to cancer onset.
†Vital status as of time of cancer registry linkage.
‡CA=Canada.
§Time between arthritis diagnosis and cancer diagnosis.
Prior to the B-cell lymphocytic leukaemia, the patient received MTX for 1 year prior to the hepatosplenic T-cell NHL, the patient was on MTX for 3.6 years, etanercept for 0.1 year, then infliximab for 1.7 years, then anakinra for 1.9 years. Prior to the post-transplant lymphoproliferative disorder, the patient had been on MTX for 1 month, etanercept for 6 months, cyclophosphamide for 1 year 3 months and infliximab for 4 months prior to the transplant, and mycophenolate, tacrolimus, rituximab and cyclophosphamide thereafter. Prior to the renal cell cancer, the patient was on MTX for 6.2 years, then leflunomide for 0.2 years, then etanercept for 4.8 years. Prior to the diagnosis of primitive neuroectodermal (Ewing) cancer, the patient was exposed to MTX for at least 20 months and leflunomide for 3 months, and was prescribed Enbrel but was not compliant.
DMARD, disease-modifying antirheumatic drug; F, female; M, male; MTX, methotrexate; NHL, non-Hodgkin's lymphoma.